The association of COVID-19 with diffuse large B-cell lymphoma: a Mendelian randomization study

ABSTRACT

With the outbreak of coronavirus disease 2019 (COVID-19), there has been an increasing focus on exploring the relationship between SARS-CoV-2 infection and tumors. However, there is no consensus on the association between COVID-19 and lymphoma. In this study, genome-wide association study (GWAS) summary data sets for COVID-19 and lymphoma were obtained from the OPEN GWAS website. Single nucleotide polymorphisms (SNPs) were selected as genetic instrument variants for fulling P < 5 × 10⁻⁸ and linkage disequilibrium [LD] r² < 0.001. Both palindromic and outlier SNPs were removed. Cochran’s Q test, the MR‒Egger intercept test, and leave-one-out analysis were employed to assess the sensitivity of the effect of COVID-19 on lymphoma. The results showed that COVID-19 patients with very severe respiratory symptoms have an increased risk of developing diffuse large B-cell lymphoma (IVW, OR = 1.765, 95% CI 1.174–2.651, P = 0.006). There was no association between COVID-19 with very severe respiratory symptoms and Hodgkin’s lymphoma or other types of non-Hodgkin’s lymphoma. No horizontal or directional pleiotropy was observed in the Mendelian randomization analysis. In conclusion, SARS-CoV-2 infection with very severe respiratory symptoms may be a potential risk factor for diffuse large B-cell lymphoma (DLBCL), and follow-up studies with larger samples are needed.

KEYWORDS:

• Coronavirus disease 2019 (COVID-19)
• diffuse large B-cell lymphoma (DLBCL)
• genome-wide association studies (GWAS)
• single nucleotide polymorphisms (SNPs)
• Mendelian randomization

Disclosure statement

No potential conflict of interest was reported by the author(s).

Supplementary material

Supplemental data for this article can be accessed online at https://doi.org/10.1080/09603123.2023.2251406.

Additional information

Funding

This work was funded by the Young Innovative Talents Project of The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University Science [grant # QC 202218], Technology Fund of Huaian City [grant # HAB202020] and Commission of Health of Jiangsu Province [grant # 2019082].